Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT00901901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially curative intervention (i.e. surgical resection or local ablation) are not eligible for this study.
Study identification
- NCT ID
- NCT00901901
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 732 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2009
- Primary completion
- Apr 16, 2012
- Completion
- May 22, 2018
- Last update posted
- May 29, 2019
2009 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Atlanta | Georgia | 30318 | — |
| Not listed | Honolulu | Hawaii | 96817 | — |
| Not listed | Maywood | Illinois | 60153-5585 | — |
| Not listed | Westwood | Kansas | 66205 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | New Orleans | Louisiana | 70112 | — |
| Not listed | Baltimore | Maryland | 21202 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02215-5450 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Minneapolis | Minnesota | 55455 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Valhalla | New York | 10595 | — |
| Not listed | Charlotte | North Carolina | 28203 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
Recently updated Carcinoma, Hepatocellular trials
Other public records listing Carcinoma, Hepatocellular. Sorted by last update posted; newest first. Not a recommendation.
- NCT05486572: Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI Recruiting
- NCT07227012: Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. Recruiting
- NCT04008797: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Active, not recruiting
- NCT04102098: A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation Active, not recruiting
- NCT05366829: Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma Recruiting
- NCT03894917: Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00901901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2019 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00901901 live on ClinicalTrials.gov.